In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
A retrospective chart review finds that Black patients with atopic dermatitis report fewer dupilumab-associated adverse ...
SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback